EUVIMEDEUVIMED entdecken
Fallbericht

Atomoxetine Induced Raynaud's Phenomenon in a 7-Year-Old Male: A Case Report

Oya Güleşen Kapan, Mustafa Kapan, Hazal Selin Soyugür

Türk Tıp Dergisi · 27.08.2026 · 11 (3) · 133-136

DOI: 10.70852/tmj.1847521 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Türk Tıp Dergisi, online erschienen am 27.08.2026. Verfasst von Oya Güleşen Kapan und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: None.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atomoxetine is one of the FDA-approved non-stimulant pharmacological agents used in the treatment of ADHD. It is commonly used in cases where patients are unresponsive to or unable to tolerate psychostimulants. The most frequently reported side effects include loss of appetite, abdominal pain, headache, and irritability. However, one of the rarely reported side effects in the literature is Raynaud’s phenomenon. In this case, we present a 7-year-old male who developed Raynaud’s phenomenon following the administration of atomoxetine.

Förderung

  • None

Zitieren

APA

Kapan, O. G., Kapan, M., & Soyugür, H. S. (2026). Atomoxetine Induced Raynaud's Phenomenon in a 7-Year-Old Male: A Case Report. Türk Tıp Dergisi, 11(3), 133-136. https://doi.org/10.70852/tmj.1847521

Vancouver

Kapan OG, Kapan M, Soyugür HS. Atomoxetine Induced Raynaud's Phenomenon in a 7-Year-Old Male: A Case Report. Türk Tıp Dergisi. 2026;11(3):133-136. doi:10.70852/tmj.1847521

BibTeX
@article{Kapan2026,
  author = {Kapan, Oya Güleşen and Kapan, Mustafa and Soyugür, Hazal Selin},
  title = {Atomoxetine Induced Raynaud's Phenomenon in a 7-Year-Old Male: A Case Report},
  journal = {Türk Tıp Dergisi},
  year = {2026},
  volume = {11},
  number = {3},
  pages = {133--136},
  doi = {10.70852/tmj.1847521}
}
Kostenlos starten →